LONDON, UK—-28th April 2010—-ExpertREACT.. Healthcare acquired infections (HAIs) continue to be a major concern to all hospital stakeholders. Beyond increased infection control and stewardship of antibiotic use, the vaccine industry is taking the possibility of further interventions seriously with major programs now in advanced clinical development. VacZine Analytics has analyzed the commercial viability of [...]
Archive of posts filed under the ExpertREACT category.
The vaccine industry in 2009: well past the $20 billion barrier
LONDON, UK—-19th February 2010—-ExpertREACT. Now that all of the major vaccine manufacturers have reported their full year 2009 results it is that customary time to analyze the industry in terms of sales value and discuss future potential/competitive dynamics. VacZine Analytics reviews the current situation.VISIT SITE.
H1N1: boost to Novartis Vaccines, the industry but for how long?
LONDON, UK—-28th January 2010—-ExpertREACT. The recent results from Novartis AG group revealed that in 2009, H1N1 vaccine sales gave an extra $1 bn to the Vaccines and Diagnostics division. This much needed boost finally lifts the division to a respectable level of profitability but will also benefit other flu players with better underlying businesses. [...]
2009 and vaccines: lots of activity, and surprises.
LONDON, UK—-31st December 2009—-ExpertREACT. 2009 was a year of unprecedented activity for the vaccine industry. Not only did existing players have to mount a rapid response to an influenza pandemic, they also had to ramp up corporate expansion to stay ahead of newcomers. Overall it was a year of many surprises but beyond the [...]
Rethinking new meningitis ACWY vaccines
LONDON, UK—-17th November 2009—-ExpertREACT. At the recent Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009), new vaccines to protect against N.meningitidis (ACWY) were discussed. Question marks around inclusion on the US infant schedule will force manufacturers to consider other penetration strategies. VacZine Analytics discusses the current issues. READ ARTICLE.
Vaccine major players – Q1 round up of results and R&D
LONDON, UK—-7th May 2010—-ExpertREACT.. After an all time high of yearly sales in FY 2009, the major vaccine companies have now announced their Q1 sales. H1N1 vaccines sales have again impacted strongly upon results adding another ~$3bn to industry fortunes. With H1N1 seemingly fading, it is only likely than new meningitis vaccines can replace this [...]